Saltar al contenido
PivotalWire
Lunes 12 oct 2026SEC · NASDAQ biomédico

Portada›Lunes 1 de diciembre de 2025

Biomédicas del NASDAQ ante la SEC, lunes 1 de diciembre de 2025

Los 34 documentos que 25 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. BFRGBullFrog AI Holdings, Inc.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…reference, our independent registered public accounting firm, in its audit report to the financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, expressed substantial doubt about our ability to continue as a going concern. See also our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, as incorporated by reference into this prospectus, including the discussion therein under “Management’s Discussion…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Recent Developments ATM Sales On April 25, 2025, we entered into an At-The-Market (“ATM”) Sales Agreement (the “ATM Agreement”) with BTIG, LLC, as sales agent (the “Agent”), with respect to an ATM offering program under which we may offer and sell through the Agent, from time to time at our sole discretion…
  2. BLTEBELITE BIO, INC424B5Nueva emisión de acciones con precioEDGAR
  3. CAMPCamp4 Therapeutics Corp424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon (which includes an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern described in Note 1 to the consolidated financial statements), included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance…
  4. KTTAPasithea Therapeutics Corp.424B4Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…development and commercialization activities. 6 The report of our independent registered public accounting firms for the fiscal year ended December 31, 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Due to the uncertainty of our ability to meet our current operating and capital expenses, in its report on our audited annual financial statements as of and for the year ended December 31, 2024, our…
  5. QCLSQ/C TECHNOLOGIES, INC.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…additional capital to fund our operations in order to continue as a going concern. In its report dated April 11, 2025, Stephano Slack LLP, our independent registered public accounting firm, expressed substantial doubt about our ability to continue as a going concern as we have suffered recurring losses from operations and have insufficient liquidity to fund our future operations. If we are unable to improve our liquidity position, we may not be able to continue as…
  6. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 28, 2025, the closing sale price per warrant of our Public Warrants was $0.22. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  7. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 28, 2025, the closing sale price per warrant of our Public Warrants was $0.22. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  8. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 28, 2025, the closing sale price per warrant of our Public Warrants was $0.22. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  9. VORVor Biopharma Inc.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated…
    En el documentoContrasplit de accionestexto original ▸…registration statement will not be reviewed or be subject to further review. On August 25, 2025, we held a special meeting of our stockholders and received Stockholder Approval. On September 18, 2025, we effected a reverse stock split of our common stock at a ratio of 1-for-20, without any adjustment to the total number of shares of common stock authorized by our certificate of incorporation. The registration statement of which this…
  10. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
  11. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
  12. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
  13. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
  14. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
  15. OCSOculis Holding AG424B3Prospecto suplementario o de reventaEDGAR
  16. VYGRVoyager Therapeutics, Inc.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

  1. MEDPMedpace Holdings, Inc.SC 13D/ACambio en participación significativaEDGAR
  2. SCLXScilex Holding CoSC 13DCambio en participación significativaEDGAR

Informes y hechos relevantes

  1. ADILADIAL PHARMACEUTICALS, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
  2. DAREDare Bioscience, Inc.8-KFin de acuerdo materialEDGAR
    En el documentoAcuerdo de licencia o colaboracióntexto original ▸…supply matters, and we agreed to be responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and product supply obligations. As a result of the termination of the License Agreement, we will not be receiving any future license fees or milestone or other payments from Bayer, and all licenses and rights we granted to Bayer will immediately terminate upon termination of the License Agreement. The foregoing summary of the License Agreement is qualified…
  3. MDCXMedicus Pharma Ltd.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that Carolyn Bonner, currently President of the Company, has also been appointed Chief Financial Officer, effective immediately. Bonner has been serving as Acting Chief Financial Officer since September 12, 2025, in addition to her responsibilities as President, providing continuity and leadership during…
    En el documentoEl ensayo alcanzó su objetivo principaltexto original ▸…testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5…
  4. OMEROMEROS CORP8-KFin de acuerdo materialEDGAR
  5. QTTBQ32 Bio Inc.8-KFin de acuerdo materialEDGAR
    En el documentoAcuerdo de licencia o colaboracióntexto original ▸…097 Asset Sale, the Company terminated its obligations under that certain exclusive license agreement, dated August 9, 2017, as amended in February 2018, September 2018, and April 2019 (the “Colorado License Agreement”), with The Regents of the University of Colorado, pursuant to which the Company obtained worldwide, royalty-bearing, sublicensable licenses under certain patents and know-how owned by Colorado and Medical University of South Carolina relating to the research, development and commercialization of ADX-097. The…
  6. AKBAAkebia Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  7. ALTAltimmune, Inc.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…Transition Date and the Separation Date, the "Transition Period"). On December 1, 2025, the Company announced that Jerome Durso, currently a member of the Company’s Board of Directors (the “Board”), has been appointed by the Board to serve as the Company’s President and Chief Executive Officer, effective as of the Transition Date. In connection with his appointment as President and Chief Executive Officer, Mr. Durso will replace Dr. Garg as the Company’s principal executive officer. Mr. Durso…
  8. ANIPANI PHARMACEUTICALS INC8-KCambio en el consejo o la direcciónEDGAR
  9. CTORCITIUS ONCOLOGY, INC.8-KOtros hechos relevantesEDGAR
  10. CTXRCitius Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
  11. CVKDCadrenal Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  12. ISPCiSpecimen Inc.8-KOtros hechos relevantesEDGAR
  13. KRSAKorsana Biosciences, Inc.8-KOtros hechos relevantesEDGAR
  14. SCLXScilex Holding Co8-KCompra o venta de activos completadaEDGAR
  15. TYRATyra Biosciences, Inc.8-KCambio en el consejo o la direcciónEDGAR
  16. XENEXenon Pharmaceuticals Inc.8-KCambio en el consejo o la direcciónEDGAR

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.